Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an announcement.
BioArctic AB announced that sales of Leqembi® totaled 23.1 billion yen in the second quarter of 2025, resulting in a significant royalty increase of approximately 280% compared to the previous year. The sales figures included a one-time stockpiling effect in China due to tariff risks, with global sales excluding this effect amounting to 17.8 billion yen. This financial performance underscores BioArctic’s strengthened market position and potential for future growth in the Alzheimer’s treatment sector.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. The company is known for developing Leqembi® (lecanemab), a drug that slows the progression of early Alzheimer’s disease. BioArctic collaborates with Eisai for global regulatory and commercialization efforts and has a diverse research portfolio targeting Parkinson’s disease, ALS, and Alzheimer’s disease using proprietary technology.
Average Trading Volume: 248,700
Technical Sentiment Signal: Buy
Current Market Cap: SEK18.66B
See more data about BIOA.B stock on TipRanks’ Stock Analysis page.